http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022023345-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7cc12b3bf7d0ca3fec1b32e7c708272 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2021-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_479aca141b93dcc7dbec9ed790141485 |
| publicationDate | 2022-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022023345-A1 |
| titleOfInvention | Compositions Comprising CD34+ Cells and Methods for Repairing a Lung Injury After Severe Virus Infection |
| abstract | The described invention provides a method for treating a subject at risk for a lung injury derived from a severe virus infection. The steps of the method include (a) receiving a subcutaneous injection of a bone marrow stimulant to mobilize CD34+ cells into the peripheral blood; (b) harvesting CD34+ cells from the peripheral blood by apheresis; (c) selecting CD34+ cells by positive selection; (d) formulating a CLBS119 cell product by suspending the selected CD34+ cells in an isotonic solution with serum ranging from 5% to 40%, inclusive and human serum albumin ranging from 0.5%-10%, inclusive, to form a pharmaceutical composition; and (e) administering the cell product to the subject. The sterile pharmaceutical composition contains a therapeutic amount of a mobilized nonexpanded, isolated population of autologous mononuclear cells enriched for CD34+ cells with a purity ranging from 55% to 100%, inclusive, which further contains a subpopulation of potent CD34+/CXCR4+ cells. The mobilized nonexpanded, isolated population of autologous mononuclear cells enriched for CD34+ cells with a purity ranging from 55% to 100%, inclusive, which further contains a subpopulation of potent CD34+/CXCR4+ cells when tested in vitro after passage through an infusion catheter after acquisition: (i) has CXCR-4 mediated chemotactic activity and moves in response to SDF-1; (ii) can form hematopoietic colonies; and (iii) is at least 80% viable. According to some embodiments, the severe virus infection is caused by influenza or a human coronavirus. |
| priorityDate | 2020-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1912.